Otsuka Pharmaceutical
Ada Patient Finder Suitability Analysis
Executive Summary
Key Finding: Two Tier 1 opportunities (Rexulti, Voyxact) with combined $150M+ Ada revenue potential at 5% capture, BUT Rexulti faces critical March 2026 patent expiry creating a 9-12 month execution window.
Portfolio Overview: 2 Tier 1 drugs | 1 Tier 2 drug | 1 Tier 3 pipeline drug | 5 excluded drugs
Total Addressable Opportunity: $200M+ annual Ada revenue (5% capture scenario across qualifying portfolio)
Executive Summary Table
| Drug |
Tier |
Fit Score |
Addressable Undiagnosed (USA) |
Ada Revenue Opportunity (5% capture) |
Key Urgency |
| Rexulti (brexpiprazole) |
Tier 1 |
8/10 |
2.85M (2.5M MDD + 350K schizophrenia) |
$128M/year |
🚨 CRITICAL: Patent expiry March 7, 2026 |
| Voyxact (sibeprenlimab-szsi) |
Tier 1 |
7/10 |
21,000 (IgA nephropathy) |
$15M/year |
✅ NOW: Approved Nov 2025, no LOE risk |
| Jynarque (tolvaptan) |
Tier 2 |
6/10 |
40,000 symptomatic (ADPKD) |
$24M/year (theoretical)
$8.4M realistic |
⏳ MODERATE: Patent Sept 2026, generic 2030 |
| Ulotaront (SEP-363856) |
Tier 3 |
7/10* |
2.85M* (schizophrenia + MDD) |
$78M/year* (Otsuka 50% share) |
⏸️ WAIT: Phase 3 ongoing (*if approved) |
| Abilify Maintena |
NO |
3/10 |
N/A |
N/A |
❌ Patent expired Oct 2024 (generic erosion) |
| Centanafadine (ADHD) |
NO |
4/10 |
7M (ADHD) |
N/A |
❌ Revenue $2.7K/year << $10K threshold |
| Lonsurf (mCRC) |
NO |
2/10 |
N/A |
N/A |
❌ Later-line oncology (no underdiagnosis) |
| Repinatrabit (PKU) |
NO |
1/10 |
0 |
N/A |
❌ Universal newborn screening (0% underdiagnosis) |
| Pocari Sweat, Nature Made |
NO |
0/10 |
N/A |
N/A |
❌ Nutraceuticals (OTC, non-prescription) |
⚠️ Time-Sensitive Action Required: Rexulti's March 7, 2026 patent expiry creates a narrow 9-12 month window to maximize branded revenue before 70-80% generic erosion. Immediate partnership launch (by March 15, 2026) is critical to capture $128M opportunity.
TIER 1: High-Priority Opportunities
Approved Indications: Schizophrenia, Major Depressive Disorder (adjunctive), Alzheimer's agitation
Commercial Status: Co-marketed with Lundbeck (Otsuka 80% US profit share)
Addressable Undiagnosed (USA)
2.85M
2.5M MDD + 350K schizophrenia
Ada Revenue (5% capture)
$128M/yr
USA only; DACH adds ~$134M
Annual Revenue (2025 est.)
$950M
Global; $700M USA share
Market Numbers
Total Condition Prevalence (USA):
- Schizophrenia: 1.55M total, 1.41M diagnosed (2022 DelveInsight)
- Major Depressive Disorder: 47.8M adults (18.3% of US adults, 2025)
- Treatment-Resistant Depression: ~14.3M (30% of MDD patients)
Undiagnosed Patients:
- Schizophrenia: ~450K undiagnosed (29% no specialist care per WHO)
- MDD: ~14-17M untreated (30-35% untreated; 25% access gap + 11-year avg delay)
Drug-Addressable Undiagnosed (Funnel):
- Schizophrenia: 450K → filter adults requiring atypical → 350K Rexulti-addressable
- MDD Adjunctive: 14-17M untreated → 30% TRD → 60% actively seeking → 2.5-3.0M Rexulti-addressable
- COMBINED: 2.85M addressable undiagnosed US patients
| Metric |
Value |
Source |
| US WAC (annual) |
$18,192/year ($1,516/month) |
Medfinder 2026 |
| Net Revenue (US blended) |
$8,500-9,500/year (50% rebate) |
Drug Channels Institute 2024 |
| Patient Finder Fee (10%) |
$900 per patient found |
Ada model |
| Patent Expiry (US) |
March 7, 2026 |
Existing deep dive |
| Generic Entry |
March 2026 (immediate) |
Expected |
| Post-LOE Impact |
70-80% revenue erosion within 18-24 months |
Industry standard |
Clinical & Diagnostic Profile
Diagnostic Delay:
- Schizophrenia: Median 11 months from symptom onset to treatment (Frontiers Psychiatry 2023)
- MDD: Average 11-year delay from onset to treatment (South Denver Therapy 2026)
- Common misdiagnoses: Unipolar depression (for schizophrenia), bipolar disorder (for MDD)
Ada Symptom Assessment Capability: 9/10 (EXCELLENT)
- ✅ Can capture: Auditory hallucinations ("hearing voices"), paranoid thoughts, social withdrawal, persistent low mood, anhedonia, failed antidepressant trials
- ✅ Specific queries: "Do you hear voices others don't?" | "Have you tried multiple antidepressants without improvement?"
- ⚠️ Challenge: Anosognosia (lack of insight) in schizophrenia may limit self-reporting; family/caregiver input valuable
Commercial & Strategic Signals
Earnings Language (Lundbeck Q3 2025):
- "Rexulti delivered 26% growth at CER...driven by strong US demand, expanding use of 300mg dose, and improved patient access programs"
- "Total prescriptions up 46%, 11.2% market share in September 2025"
- ⚠️ NO explicit language about patient finding or diagnostic delay in earnings
Company Motivation Score: 7/10
- Pre-LOE urgency HIGH (maximizing remaining branded revenue through Q1 2026)
- DTC campaigns and patient access programs suggest awareness of diagnostic gaps
- BUT: No explicit "patient finding" initiatives = opportunity for Ada to fill gap
Patient Finder Opportunity Assessment
| Market |
Addressable Undiagnosed |
1% Capture Ada Revenue |
5% Capture Ada Revenue |
| USA - Schizophrenia |
350,000 |
$3.15M/year |
$15.75M/year |
| USA - MDD Adjunctive |
2,500,000 |
$22.5M/year |
$112.5M/year |
| USA TOTAL |
2,850,000 |
$25.65M/year |
$128.25M/year |
| DACH (5% only) |
~1.88M |
N/A |
~$134M/year |
Pitch Hook: Nearly half of people with schizophrenia wait over 11 months before seeking treatment, while those with treatment-resistant depression face an average 11-year delay—Ada can identify these patients through symptom patterns and connect them to Rexulti therapy, unlocking $150-200M in annual revenue before March 2026 patent expiry.
⚠️ CRITICAL URGENCY: Launch by March 15, 2026 (before patent expiry). Post-LOE fit score drops to 3/10 as generic erosion reduces net revenue to <$3,000/year per patient. This is a 9-12 month window ONLY.
Action Required
- Timeline: Initiate partnership by March 15, 2026 (14 days from report date)
- Target: Focus on MDD adjunctive (2.5M addressable >> 350K schizophrenia)
- Channel: Primary care depression screening, psychiatric referrals
- Urgency: Maximum 9-12 month branded window before generic erosion eliminates economics
Approved Indication: IgA Nephropathy (IgAN) - reduction of proteinuria in adults at risk of rapid disease progression
Commercial Status: 100% Otsuka-owned (no co-marketing)
FDA Approval: December 2, 2025 (accelerated approval)
Addressable Undiagnosed (USA)
21,000
Symptomatic IgAN patients
Ada Revenue (5% capture)
$15M/yr
USA; DACH adds ~$6.6M
Net Revenue Per Patient
$142,500
Ultra-high value (est.)
Market Numbers
Total Condition Prevalence (USA):
- Diagnosed IgAN: ~194,000 prevalent cases (2022 Kaiser Permanente)
- Incidence: 1.4 per 100,000 person-years; higher in Asian/Pacific Islander (4.5) and Hispanic (1.7)
- IgAN is the most common primary glomerulonephritis worldwide
Undiagnosed Patients:
- Underdiagnosis rate: 20-30% (kidney biopsy required; many asymptomatic mild cases not biopsied)
- Calculation: 194,000 × 0.25 = ~48,500 undiagnosed US patients
- Rationale: Early IgAN presents with microscopic hematuria or mild proteinuria (asymptomatic); many not biopsied until eGFR decline
Drug-Addressable Undiagnosed (Funnel):
- Total undiagnosed: ~48,500
- Filter symptomatic (gross hematuria, foamy urine, persistent proteinuria): ~50-60% = 24,000-29,000
- Filter adults ≥18 years (Voyxact label): ~90% = 21,600-26,100
- Filter "at risk of rapid progression" (FDA label): ~70-80% eligible = ~15,000-21,000
- Voyxact-addressable: ~18,000-25,000 undiagnosed (conservative midpoint: 21,000)
| Metric |
Value |
Notes/Source |
| US WAC (annual, estimated) |
$240,000-280,000/year |
NOT YET DISCLOSED; est. based on Filspari, Tarpeyo, specialty mAb comparables |
| Net Revenue (US blended, estimated) |
$130,000-155,000/year (45% rebate) |
Midpoint: $142,500/year |
| Patient Finder Fee (10%) |
$13,000-15,500 per patient found |
Ultra-high value opportunity |
| Patent Expiry (US/EU) |
2040+ |
Newly approved first-in-class mAb; 20-year composition-of-matter patents |
| Generic Entry |
2040+ (NO near-term LOE risk) |
Multi-decade exclusivity |
| Peak Revenue Estimate |
$500M-1.0B+ |
Analyst estimates; IgAN market growing to $9.7B by 2034 |
Clinical & Diagnostic Profile
Symptoms:
- Early IgAN (asymptomatic): Microscopic hematuria, mild proteinuria (detected on routine urinalysis)
- Symptomatic IgAN:
- Gross hematuria (visible blood in urine), often post-upper respiratory infection
- Foamy urine (proteinuria)
- Hypertension (>70% of patients)
- Flank pain, edema (advanced disease)
Diagnostic Delay:
- Median delay from first clinical sign to diagnosis: 5 months (ISN 2023)
- Late diagnosis common: 68% have eGFR <60 at biopsy (advanced disease)
- Interpretation: Short symptomatic delay BUT many asymptomatic cases progress undetected for years
Ada Symptom Assessment Capability: 6/10 (MODERATE)
- ✅ Can capture: "Have you seen blood in your urine?" | "Is your urine foamy?" | "Do you have high blood pressure?" | "Have you had recent colds before urine changes?"
- ⚠️ Challenges:
- Asymptomatic early disease: Microscopic hematuria and mild proteinuria NOT self-reported (requires lab test)
- Diagnosis requires kidney biopsy: Ada can trigger urine testing and nephrology referral, but NOT directly diagnose IgAN
- ✅ Value: Identify symptomatic undiagnosed cases with gross hematuria, prompt urinalysis and nephrology referral
Commercial & Strategic Signals
Otsuka FY2025 Language:
- Sibeprenlimab cited as "first-in-class breakthrough" with "blockbuster potential"
- Emphasis on "large unmet need" in IgAN
- ⚠️ NO explicit patient-finding language in investor materials
- Interpretation: Company focused on nephrology KOL adoption, clinical data dissemination = greenfield for Ada patient-finding partnership
Strategic Context:
- Otsuka acquired Visterra for $430M (2018) to obtain sibeprenlimab pipeline
- Validates nephrology franchise commitment alongside Jynarque
- Offsets ADPKD LOE risk with IgAN new launch
- Company Motivation Score: 8/10 (newly approved first-in-class asset; strategic priority; NO current patient-finding = opportunity)
Competitive Landscape
| Competitor |
Status |
Key Notes |
| Tarpeyo (budesonide, Calliditas) |
Approved Dec 2021 |
Current market leader among recent IgAN launches; oral corticosteroid |
| Fabhalta (iptacopan, Novartis) |
Approved Aug 2024 |
38.3% proteinuria reduction (Phase III APPLAUSE-IgAN) |
| Filspari (sparsentan, Travere) |
Approved Feb 2023 |
Dual endothelin/angiotensin receptor antagonist |
| Vanrafia (atrasentan, Novartis) |
Approved April 2025 |
Reduces proteinuria; Phase III ALIGN showed eGFR benefit |
| Atacicept (Vera Therapeutics) |
Phase 3 (ORIGIN complete) |
Breakthrough Therapy Designation; targets B/plasma cells; potential best-in-class |
Market Context: IgAN market estimated at $878M (7MM, 2025) growing to $9.7B by 2034. Voyxact is first anti-APRIL mAb with 51% proteinuria reduction (Phase 3 interim), competitive with leading therapies. Market fragmentation risk with 6+ approved therapies, but large TAM supports multiple winners.
Patient Finder Opportunity Assessment
| Market |
Addressable Undiagnosed |
1% Capture Ada Revenue |
5% Capture Ada Revenue |
| USA |
21,000 |
$2.99M/year |
$14.96M/year |
| DACH |
6,300 |
N/A |
$6.55M/year |
| TOTAL (USA + DACH) |
27,300 |
— |
$21-22M/year |
Pitch Hook: IgA nephropathy remains undetected in 20-30% of patients until advanced kidney damage, with a median 5-month delay even for symptomatic cases—Ada can identify patients with visible blood in urine or foamy urine post-respiratory infections, connecting them to Voyxact therapy at $142,500 per patient annually.
Action Required
- Timeline: Initiate Q2 2026 partnership (align with Otsuka nephrology commercial launch)
- Target: Nephrologists and primary care with hematuria/proteinuria pathways
- Differentiation: First anti-APRIL mAb; no LOE risk for decades
- Strategic Value: Ultra-high per-patient revenue ($14,250 per patient found) + multi-decade exclusivity = ideal long-term partnership
TIER 2: Moderate-Priority Opportunities
Approved Indication: Autosomal Dominant Polycystic Kidney Disease (ADPKD) - slow kidney function decline in adults at risk of rapid progression
Commercial Status: 100% Otsuka-owned
Addressable Undiagnosed (USA)
40,000
Symptomatic subset only (~15% of 258K total)
Ada Revenue (5% capture)
$24M/yr
Theoretical; $8.4M realistic
Annual Revenue (FY2024)
$1.47B
US sales only
Market Numbers
Total Condition Prevalence (USA):
- True genetic prevalence: ~1 in 1,072 individuals (0.093%) = ~308,000 US adults (PMC 12020221)
- Diagnosed cases: Much lower (~25,000-50,000 based on Medicare data, treatment market demand)
- Underdiagnosis gap: 84% (true prevalence 308K vs. diagnosed 50K = ~258,000 undiagnosed)
Why Such High Underdiagnosis?
- ADPKD is asymptomatic until 30s-40s when kidney function declines
- Many undetected until ESRD or incidental imaging (CT/ultrasound for unrelated reason)
- Disease present at birth (autosomal dominant), but symptoms delayed decades
Drug-Addressable Undiagnosed (Funnel):
- Total undiagnosed: ~258,000
- Filter symptomatic cases (flank pain, hematuria, hypertension, palpable kidneys): ~30-40% = ~77,000-103,000
- Filter adults with rapid progression risk (PROPKD score >6, htTKV growth, eGFR slope): ~50-60% of symptomatic = ~38,500-61,800
- Filter no contraindications (liver disease, pregnancy, inability to sense thirst): ~80% = ~30,800-49,440
- Jynarque-addressable: ~40,000 undiagnosed US patients (conservative midpoint)
⚠️ CRITICAL LIMITATION: Jynarque requires evidence of rapid progression (imaging, eGFR decline). Asymptomatic undiagnosed majority (85% of 258K) NOT eligible. Ada can ONLY find symptomatic minority (~40K) with obvious symptoms (flank pain, hematuria, family history).
| Metric |
Value |
Source/Notes |
| US WAC (annual) |
>$50,000/year (reported); est. $180,000-240,000/year |
Based on $1.467B revenue ÷ patient count |
| Net Revenue (US blended) |
$110,000-130,000/year (45% rebate) |
Midpoint: $120,000/year |
| Patient Finder Fee (10%) |
$12,000 per patient found |
Ultra-high value |
| US Orphan Exclusivity |
Expired April 23, 2025 |
— |
| US Patents |
Expire September 2026 |
Near-term LOE risk |
| Generic Entry Estimate |
April 7, 2030 (delayed by regulatory exclusivities) |
3-4 year window post-patent expiry |
| FY2024 Revenue (US) |
$1.467 billion |
AInvest 2024 |
Clinical & Diagnostic Profile
Symptoms:
- Early ADPKD (asymptomatic): No symptoms; detected incidentally on imaging or family screening
- Symptomatic ADPKD: Flank/back pain (cyst enlargement, rupture), hematuria, hypertension (80% before renal decline), palpable kidneys, UTIs, kidney stones
Diagnostic Delay:
- Median time from first clinical sign to diagnosis: 5 months (if symptomatic)
- BUT: First symptoms often in 30s-40s, decades after disease onset at birth
- Underdiagnosis: 84% remain undiagnosed until advanced CKD or incidental imaging
Ada Symptom Assessment Capability: 5/10 (MODERATE-LOW)
- ✅ Can capture (symptomatic cases): "Do you have flank or back pain?" | "Have you seen blood in your urine?" | "Do you have high blood pressure?" | "Does anyone in your family have kidney disease or polycystic kidneys?" (family history critical)
- ⚠️ Major Challenge: Asymptomatic early disease (most undiagnosed cases)
- 84% undiagnosed = predominantly asymptomatic until 30s-40s
- Ada CANNOT find pre-symptomatic cases (requires imaging or genetic testing)
- ✅ Value: Identify symptomatic undiagnosed minority (flank pain + hematuria + family history → nephrology referral for ultrasound)
Patient Finder Opportunity Assessment
| Market |
Addressable |
1% Capture |
5% Capture (Theoretical) |
5% Capture (Realistic*) |
| USA |
40,000 symptomatic |
$4.8M/year |
$24M/year |
$8.4M/year |
| DACH |
56,500 symptomatic |
N/A |
$45.2M/year |
$15.8M/year |
| TOTAL |
— |
— |
$69M/year |
~$24M/year |
*Realistic Adjustment: If Ada can ONLY find 30-40% of addressable (symptomatic cases with obvious symptoms), reduce by 60-70%. This accounts for:
- Many symptomatic cases have vague symptoms (mild hypertension) not specific enough for Ada identification
- Family history required for strong referral signal
- Asymptomatic majority (85%) completely out of reach for symptom-based finding
Pitch Hook: Autosomal dominant polycystic kidney disease goes undetected in 84% of cases until advanced kidney failure, but Ada can identify the symptomatic subset—patients with flank pain, blood in urine, and family history of kidney disease—connecting them to $120,000/year Jynarque therapy before dialysis becomes inevitable.
Action Required
- Priority: MODERATE (Tier 2)
- Focus: Family history + symptomatic cases (flank pain, hematuria, hypertension in young adults)
- Partner with: Genetic counseling networks, nephrology specialists
- Acknowledge limitation: Cannot find asymptomatic majority (84% of undiagnosed); symptom-based detection limited to ~15-30% of undiagnosed pool
- Economics: Strong per-patient revenue ($12,000 per patient found) but narrow addressable funnel
- Timing: Pre-2030 focus (generic entry 2030 will erode economics)
TIER 3: Opportunistic / Pipeline
Indication: Schizophrenia (Phase 3 ongoing); Major Depressive Disorder adjunctive (Phase 3 initiating)
Commercial Status: Co-developed with Sunovion (50/50 profit share)
Mechanism: TAAR1 agonist (trace amine-associated receptor 1) + 5-HT1A activity; first-in-class, non-D2 mechanism
Fit Score (IF APPROVED)
7/10*
Addressable Undiagnosed (USA)
2.85M*
Same as Rexulti (if approved)
Ada Revenue (5% capture)
$78M/yr*
Otsuka 50% share (if approved)
Approval Timeline
2027-2028
Estimated (Phase 3 ongoing)
Phase 3 Status
Key Trial (NCT06894212):
- Randomized, double-blind, placebo-controlled
- Doses: 75mg/day and 100mg/day vs placebo
- Population: Acutely psychotic adults with schizophrenia (PANSS total ≥80, CGI-S ≥4, recent hospitalization required)
- Primary endpoint: Change in PANSS total score at Week 6
- Status: Ongoing/recruiting; NO RESULTS YET
- Source: ClinicalTrials.gov
Prior Evidence:
- Phase 2/3 trials (NCT04825860) tested 50mg and 75mg doses vs placebo; no published results in search data
- 100mg showed greatest efficacy in acute schizophrenia with favorable safety (smaller effect sizes)
- Mechanism: TAAR1 agonism differs from dopamine D2 blockers; potentially fewer side effects (weight gain, metabolic)
Market Opportunity (IF APPROVED)
Addressable Market: Same as Rexulti (350K schizophrenia + 2.5M TRD = 2.85M US addressable)
| Metric |
Value (ESTIMATED) |
Notes |
| Pricing (est.) |
Similar to Rexulti ($1,600-2,000/month WAC) |
Assumption based on CNS atypical comparables |
| Net Revenue (est.) |
$10,000-13,000/year (blended) |
After 47% rebate |
| Patient Finder Fee (10%) |
$1,150 per patient (gross) |
— |
| Otsuka Share (50/50 split) |
$575 per patient found |
50% Otsuka, 50% Sunovion |
| Ada Revenue (5% capture, USA) |
$156M gross → $78M Otsuka share |
Contingent on approval |
Scoring (IF APPROVED)
| Dimension |
Score |
Notes |
| Ada Surface Ability |
9/10 |
Same as Rexulti (excellent symptom capture) |
| Company Motivation |
7/10 |
$890M Sunovion deal signals priority, BUT 50/50 split reduces Otsuka upside |
| Pipeline Risk |
5/10 |
Phase 3 ongoing, approval NOT guaranteed |
| Patent Protection |
10/10 |
Protected through 2040+ (first-in-class TAAR1) |
| Overall Fit Score |
7/10 |
Contingent on approval (2027-2028 est.) |
Recommendation:
- WAIT for Phase 3 data before active pursuit
- Prepare partnership framework (50/50 split-aware pricing)
- Activate IF/WHEN Phase 3 positive and NDA submitted (estimated 2027-2028)
- Strong fit IF approved: same diagnostic delay/underdiagnosis as Rexulti, improved metabolic profile, multi-decade patent protection
Excluded Drugs (NO TIER)
5. ABILIFY MAINTENA (aripiprazole LAI)
Tier: NO - EXCLUDE
Rationale: Patent expired October 2024; generic competition active; revenue declining 12% annually; post-LOE net revenue <$5,000/year per patient FAILS $10K threshold
| Metric |
Value |
| FY2024 Revenue |
$1.5B global |
| FY2025 Projection |
$1.3B (-12%) |
| 2029 Forecast |
$459M (negative 21% CAGR) |
| US/EU Patent Expiry |
October 2024 |
| Generic Entry |
Active NOW |
Conclusion: No Patient Finder fit; generic market does not support premium patient-finding economics. Per-patient revenue post-LOE insufficient.
6. CENTANAFADINE (ADHD)
Tier: NO - EXCLUDE
Rationale: Per-patient net revenue $2,400-3,000/year FAILS $10K threshold by 70%; not economically viable for premium patient-finding model despite excellent clinical fit
| Metric |
Value |
| NDA Status |
Submitted, PDUFA July 24, 2026 (priority review) |
| Pricing Estimate |
$350-500/month WAC ($4,800-6,000/year gross) |
| Net Revenue |
$2,400-3,000/year (50% rebate) |
| Patient Finder Fee (10%) |
$270 per patient (NOT viable) |
| ADHD Undiagnosed (USA) |
~5-7M adults (diagnostic delay 10-15 years) |
| Ada Capability |
9/10 (excellent symptom capture) |
Conclusion: Strong clinical fit (diagnostic delay, underdiagnosis, Ada surfacing) BUT low revenue eliminates economic viability. Consider ONLY if Otsuka accepts flat-fee or <5% revenue share model for volume play; otherwise economically unviable.
7. LONSURF (trifluridine/tipiracil)
Tier: NO - EXCLUDE
Rationale: Later-line metastatic colorectal cancer (3rd+ line post-chemo); patients already diagnosed and in oncologist care; NO underdiagnosis; Ada value misaligned
- Indication: Metastatic colorectal cancer (mCRC), 3rd+ line after FOLFOX, bevacizumab, anti-EGFR (if RAS wild-type)
- FY2023 Revenue: ¥62.5B ($417M) global via Taiho subsidiary
- Why NO Fit:
- No underdiagnosis: mCRC patients definitively staged via imaging; already in oncologist care
- Later-line therapy: Lonsurf targets patients who have exhausted 1st/2nd-line therapies
- Ada value misalignment: Ada's strength is EARLY detection (pre-metastatic screening), NOT identifying which mCRC patients should advance to 3rd-line therapy (oncologist decision)
- Alternative Ada Role: Early CRC detection (rectal bleeding, bowel habit changes) → colonoscopy screening → BUT benefits 1st-line surgery/chemo competitors, NOT Lonsurf specifically
Conclusion: Ada Patient Finder does NOT fit later-line oncology use case; natural disease progression eventually reaches Lonsurf WITHOUT Ada involvement.
8. REPINATRABIT (JNT-517, PKU)
Tier: NO - EXCLUDE
Rationale: Phenylketonuria (PKU) has UNIVERSAL newborn screening in US/EU/Japan; ~0% underdiagnosis in developed countries; diagnosed within days of birth (median <15 days); NO diagnostic delay; Ada CANNOT add value
| Metric |
Value |
| Status |
Phase 3 initiated December 2025 (PheORD trial) |
| US Prevalence |
18,800 diagnosed cases (2024) |
| Incidence |
1 in 10,000-15,000 live births |
| Newborn Screening |
UNIVERSAL in US, EU, Japan (mandatory blood spot test within 24-48 hours) |
| Underdiagnosis Rate |
~0% in developed countries |
| Diagnostic Delay |
Median <15 days (target: <3 months) |
| Pricing Estimate |
$80,000-120,000/year WAC (orphan rare disease) |
| Net Revenue |
$60,000-90,000/year (meets threshold) |
Conclusion: Despite high revenue meeting $10K threshold, PKU's universal newborn screening eliminates patient-finding opportunity in developed markets. Symptomatic PKU (intellectual disability, seizures) only occurs if newborn screening MISSED (exceedingly rare). No addressable undiagnosed population.
9. POCARI SWEAT & NATURE MADE (Nutraceuticals)
Tier: NO - EXCLUDE
Rationale: Consumer products; non-prescription; no disease indication; not drug therapy
- Pocari Sweat: Electrolyte beverage, OTC; revenue part of ¥577.7B nutraceutical segment (FY2025); no prescription, no diagnostic delay, no patient-finding relevance
- Nature Made: Vitamins/supplements, OTC; US e-commerce growth driver; no prescription, no disease indication
Conclusion: Exclude all nutraceuticals from Patient Finder analysis (not drug therapy; no patient identification use case).
Strategic Recommendations
Immediate Actions (Q1-Q2 2026)
1. Rexulti Pre-LOE Blitz:
- Launch by March 15, 2026 (before patent expiry)
- Target: MDD adjunctive (2.5M addressable > schizophrenia 350K)
- Channel: Primary care depression screening, psychiatric referrals
- Timeline: 9-12 month window maximum
- Key message: "Have you tried multiple antidepressants without improvement?" → TRD identification → Rexulti adjunctive consideration
2. Voyxact Launch Partnership:
- Initiate Q2 2026 (align with Otsuka nephrology commercial launch)
- Target: Nephrologists, primary care with hematuria/proteinuria pathways
- Differentiation: First anti-APRIL mAb, no generic risk for decades
- Key message: "Have you seen blood in your urine, especially after a cold or respiratory infection?" → IgAN identification → nephrology referral for urinalysis/biopsy
Medium-Term (2026-2027)
3. Jynarque Symptomatic Finding:
- Focus: Family history + symptomatic cases (flank pain, hematuria, hypertension)
- Partner with: Genetic counseling, nephrology networks
- Acknowledge limitation: Cannot find asymptomatic majority (84% undiagnosed)
- Key message: "Do you have family members with polycystic kidneys? Do you have flank pain or blood in urine?" → ADPKD screening → renal ultrasound/genetic testing
Pipeline Monitoring (2027-2028)
4. Ulotaront Phase 3 Watch:
- Prepare: Partnership framework
- Activate: IF/WHEN Phase 3 positive and NDA submitted
- Structure: 50/50 split-aware pricing (Otsuka receives $575 per patient found vs. $900 if solo)
Deprioritize / Exclude
- ❌ Abilify Maintena (post-LOE generic erosion, revenue insufficient)
- ❌ Centanafadine (low revenue $2.7K/year << $10K threshold; consider only for flat-fee pilot if Otsuka requests)
- ❌ Lonsurf (no patient-finding fit for later-line oncology)
- ❌ Repinatrabit (no underdiagnosis due to universal newborn screening)
- ❌ Nutraceuticals (OTC, non-prescription, no disease indication)